Chinese scientists found that the new method "tumor immunotherapy

March 19, 2016

Source: xinhua news agency

Shanghai, March 18 (xinhua) (reporter Lynn) Shanghai life science college of Chinese academy of sciences institute of biochemistry and cell biology rain gemany team and bo-liang li group, recently found a new way to promote T cell antitumor effect, namely by regulatory T cells key targets change its metabolic state. As a result, the team also found a new drug targets, for the development of new methods of "tumor immunotherapy" laid a foundation. Related work has been published online on the 17th international authoritative journal nature.

It is understood that the appearance of the tumor and the disorders of the body's immune system have a close relationship, the scientific community is generally believed that "tumor immunotherapy" likely from the repair of the body's immune system to provide a cure for cancer, "root", "the ultimate antidote. And T cells are important in the monitoring and kill tumor, clinical often by increasing the activity of T cells to treat tumor.

Rain march and bo-liang li team in the research on the antitumor immune function of T cells found that T cell metabolic pathways of cholesterol esterification enzyme (ACAT1) is a very good control targets, inhibit its activity can greatly improve the antitumor function of killer T cells. Meanwhile, in experiments with mice, the scientists found that small molecule inhibitors of ACAT1 Avasimibe have good antitumor effect. If the inhibitor with the existing clinical tumor immunotherapy drugs used in combination with anti - PD - 1, the effect is better, on the one hand, can improve the effectiveness of the treatment of tumor, on the other hand can also reduce the dosage, toxic and side effects.

Hong-yang wang academicians think Oriental liver and gallbladder surgery hospital, the study opens the "tumor immunotherapy" a whole new field of study, prove that the tumor cell metabolism, immune response plays a key role, found ACAT1 this new drug targets at the same time, reveals the application prospect of ACAT1 small molecule inhibitors, for tumor immunotherapy provides a new way of thinking and new methods.